{"filing":{"accession_number":"0001493152-26-024517","cik":"0001971532","ticker":"TELO","company_name":"Telomir Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-05-20","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226024517/form8-k.htm"},"events":[{"id":9880,"run_id":8659,"accession_number":"0001493152-26-024517","anchor_item_number":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"Telomir Pharmaceuticals disclosed publication of a peer-reviewed preclinical study on its lead candidate Telomir-1 in Wilson's disease, demonstrating positive efficacy signals including reductions in oxidative stress, hepatic copper accumulation, and improvements in survival outcomes. While this is a positive development for a clinical-stage biotech company, it does not fit neatly into the standard 8-K taxonomy—it is neither an earnings release (no financial results), nor an executive change, M\u0026A activity, or other discrete event type. The disclosure is material to investors evaluating the company's pipeline prospects, warranting classification as other_material.","company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","filing_date":"2026-05-20","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":703,"accession_number":"0001493152-26-024517","item_number":null,"item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"Telomir Pharmaceuticals disclosed publication of a peer-reviewed preclinical study on its lead candidate Telomir-1 in Wilson's disease, demonstrating positive efficacy signals including reductions in oxidative stress, hepatic copper accumulation, and improvements in survival outcomes. While this is a positive development for a clinical-stage biotech company, it does not fit neatly into the standard 8-K taxonomy—it is neither an earnings release (no financial results), nor an executive change, M\u0026A activity, or other discrete event type. The disclosure is material to investors evaluating the company's pipeline prospects, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:52:58.882204+00:00","company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","filing_date":"2026-05-20"}]}